Total patients | Centre A | Centre B | Centre C | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
ACOR-1 (N = 120) | ACOR-2 (N = 120) | p-value | ACOR-1 (N = 40) | ACOR-2 (N = 40) | p-value | ACOR-1 (N = 120) | ACOR-2 (N = 120) | p-value | ACOR-1 (N = 40) | ACOR-2 (N = 40) | p-value | |
Planned treatment | ||||||||||||
RT + chemo | 115 (95.8%) | 107 (89.2%) | 0.086 | 37 (92.5%) | 34 (85%) | 0.48 | 39 (97.5%) | 39 (97.5%) | > 0.99 | 39 (97.5%) | 34 (85%) | 0.11 |
RT | 5 (4.2%) | 13 (10.8%) | 3 (7.5%) | 6 (15%) | 1 (2.5%) | 1 (2.5%) | 1 (2.5%) | 6 (15%) | ||||
Type of radiotherapy | ||||||||||||
LCRT | 108 (90%) | 102 (85%) | 0.33 | 36 (90%) | 32 (80%) | 0.35 | 40 (100%) | 38 (95%) | 0.47 | 32 (80%) | 32 (80%) | > 0.99 |
SCRT | 12 (10%) | 18 (15%) | 4 (10%) | 8 (20%) | 0 (0%) | 2 (5%) | 8 (20%) | 8 (20%) | ||||
Type of indicated technology | ||||||||||||
3D | 117 (97.5%) | 95 (79.2%) | < 0.001‡ | 40 (100%) | 23 (57.5%) | < 0.001‡ | 40 (100%) | 38 (95%) | 0.47 | 37 (92.5%) | 34 (85%) | 0.48 |
VMAT | 3 (2.5%) | 25 (20.8%) | 0 (0%) | 17 (42.5%) | 0 (0%) | 2 (5%) | 3 (7.5%) | 6 (15%) | ||||
Total dosage administered | ||||||||||||
25 Gy | 12 (10.3%) | 18 (15.3%) | 0.034* | 4 (10.3%) | 8 (21.1%) | < 0.001‡ | 0 (0%) | 2 (5%) | 0.36 | 8 (21.1%) | 8 (20%) | 0.57 |
45 Gy | 34 (29.1%) | 15 (12.7%) | 34 (87.2%) | 14 (36.8%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (2.5%) | ||||
50 Gy | 3 (2.6%) | 6 (5.1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 3 (7.9%) | 6 (15%) | ||||
50.4 Gy | 63 (53.8%) | 74 (62.7%) | 1 (2.6%) | 16 (42.1%) | 35 (87.5%) | 33 (82.5%) | 27 (71.1%) | 25 (62.5%) | ||||
54 Gy | 5 (4.3%) | 5 (4.2%) | 0 (0%) | 0 (0%) | 5 (12.5%) | 5 (12.5%) | 0 (0%) | 0 (0%) | ||||
Prolongation of treatment time (if SCRT) | ||||||||||||
< 3 days | 12 (100%) | 17 (94.4%) | > 0.99 | 4 (100%) | 8 (100%) | 0.25 | 0 (NaN%) | 2 (100%) | 0.16 | 8 (100%) | 7 (87.5%) | > 0.99 |
3–5 days | 0 (0%) | 1 (5.6%) | 0 (0%) | 0 (0%) | 0 (NaN%) | 0 (0%) | 0 (0%) | 1 (12.5%) | ||||
Prolongation of treatment time (if LCRT) | ||||||||||||
< 3 days | 62 (57.4%) | 58 (56.9%) | 0.96 | 19 (52.8%) | 20 (62.5%) | 0.22 | 31 (77.5%) | 27 (71.1%) | 0.53 | 12 (37.5%) | 11 (34.4%) | 0.90 |
3–5 days | 32 (29.6%) | 31 (30.4%) | 11 (30.6%) | 10 (31.2%) | 9 (22.5%) | 9 (23.7%) | 12 (37.5%) | 12 (37.5%) | ||||
6–7 days | 4 (3.7%) | 5 (4.9%) | 0 (0%) | 1 (3.1%) | 0 (0%) | 1 (2.6%) | 4 (12.5%) | 3 (9.4%) | ||||
> 7 days | 10 (9.3%) | 8 (7.8%) | 6 (16.7%) | 1 (3.1%) | 0 (0%) | 1 (2.6%) | 4 (12.5%) | 6 (18.8%) | ||||
Week day when treatment was finalised | ||||||||||||
Monday | 17 (14.2%) | 7 (5.8%) | 0.24 | 6 (15%) | 1 (2.5%) | 0.16 | 6 (15%) | 3 (7.5%) | 0.68 | 5 (12.5%) | 3 (7.5%) | 0.28 |
Tuesday | 24 (20%) | 22 (18.3%) | 11 (27.5%) | 11 (27.5%) | 5 (12.5%) | 6 (15%) | 8 (20%) | 5 (12.5%) | ||||
Wednesday | 13 (10.8%) | 12 (10%) | 5 (12.5%) | 5 (12.5%) | 2 (5%) | 1 (2.5%) | 6 (15%) | 6 (15%) | ||||
Thursday | 24 (20%) | 27 (22.5%) | 8 (20%) | 5 (12.5%) | 11 (27.5%) | 9 (22.5%) | 5 (12.5%) | 13 (32.5%) | ||||
Friday | 42 (35%) | 52 (43.3%) | 10 (25%) | 18 (45%) | 16 (40%) | 21 (52.5%) | 16 (40%) | 13 (32.5%) |